medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2022, Number 3

<< Back

Alerg Asma Inmunol Pediatr 2022; 31 (3)

A fulminant case of MIS-C related macrophage activation syndrome mimicking acute appendicitis in a teenage patient

García-Domínguez M, Anaya-Enríquez N, Peña E, Arce-Cabrera D

Language: Spanish
References: 13
Page: 94-97
PDF size: 183.17 Kb.


ABSTRACT

Introduction: multisystem inflammatory syndrome in children (MIS-C) is a clinical entity with hyperinflammatory response in children that can affect any organ, including the gastrointestinal system in 80-90% of the cases. Case presentation: an 11-years-old girl presented with fever, lethargy, shock, and abdominal pain with suspicion of acute appendicitis. She underwent abdominal surgery without suggestive findings of appendicitis. She developed multi-organ failure afterwards with elevation of inflammatory markers. The diagnosis of MIS-C was made, complicated by macrophage activation syndrome without response to established treatment. Conclusion: acute abdomen or suspicion of acute appendicitis with elevated inflammation markers can be a clinical presentation of MIS-C, which can confuse the physicians and delay the diagnosis and treatment complicating the clinical course with life-threatening conditions, such as macrophage activation syndrome (MAS). In this case report, the diagnosis of MIS-C was established, however, the evolution was fatal despite established treatment.


REFERENCES

  1. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 395 (10239): 1771-1778. doi: 10.1016/S0140-6736(20)31103-X.

  2. Feldstein LR, Tenforde MW, Friedman KG et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021; 325 (11): 1074-1087. doi: 10.1001/jama.2021.2091.

  3. McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021; 385 (1): 11-22. doi: 10.1056/NEJMoa2102968.

  4. Assa A, Benninga MA, Borrelli O et al. Gastrointestinal perspective of coronavirus disease 2019 in children-an updated review. J Pediatr Gastroenterol Nutr. 2021; 73 (3): 299-305. doi: 10.1097/MPG.0000000000003204.

  5. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020; 73 (5): 1231-1240. doi: 10.1016/j.jhep.2020.06.006.

  6. Zou H, Lu J, Liu J, Wong JH, Cheng S, Li Q et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2021; 102: 319-326. doi: 10.1016/j.ijid.2020.11.145.

  7. Khesrani LS, Chana K, Sadar FZ, Dahdouh A, Ladjadj Y, Bouguermouh D. Intestinal ischemia secondary to Covid-19. J Pediatr Surg Case Rep. 2020; 61: 101604. doi: 10.1016/j.epsc.2020.101604.

  8. Lishman J, Kohler C, de Vos C, van der Zalm MM, Itana J, Redfern A et al. Acute appendicitis in multisystem inflammatory syndrome in children with COVID-19. Pediatr Infect Dis J. 2020; 39 (12): e472-e473. doi: 10.1097/INF.0000000000002900.

  9. Valitutti F, Verde A, Pepe A, Sorrentino E, Veneruso D, Ranucci G et al. Multisystem inflammatory syndrome in children. An emerging clinical challenge for pediatric surgeons in the COVID 19 era. J Pediatr Surg Case Rep. 2021; 69: 101838. doi: 10.1016/j.epsc.2021.101838.

  10. Yock-Corrales A, Lenzi J, Ulloa-Gutiérrez R, Gómez-Vargas J, Antúnez-Montes OY, Rios Aida JA et al. Acute abdomen and appendicitis in 1010 pediatric patients with COVID-19 or MIS-C: a multinational experience from Latin America. Pediatr Infect Dis J. 2021; 40 (10): e364-e369. doi: 10.1097/INF.0000000000003240.

  11. García-Domínguez M, Torres CG, Carreón-Guerrero JM, Quibrera J, Arce-Cabrera D, Yamazaki-Nakashimada M. Macrophage activation syndrome in two infants with multisystem inflammatory syndrome in children. Pediatr Blood Cancer. 2021; 68 (10): e29199. doi: 10.1002/pbc.29199.

  12. Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P et al. Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol. Front Med (Lausanne). 2020; 7: 466. doi: 10.3389/fmed.2020.00466.

  13. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020; 146 (1): 137-146.e3. doi: 10.1016/j.jaci.2020.05.019.




2020     |     www.medigraphic.com